UNSPSC 51281637: Bekanamycin sulfate

This classification denotes the sulfate form of an aminoglycoside antibiotic with the molecular structure C18H37N5O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 15JT14C3GI chemically known as (1r,2s,3s,4r,6s)-4,6-diamino-3-((3-amino-3-deoxy-.alpha.-d-glucopyranosyl)oxy)-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranoside, but more commonly known as bekanamycin, which bears US NIH Compound Identifier 816.

UNSPSC 51281637 Bekanamycin sulfate is a Commodity code that nominally names a specific aminoglycoside antibiotic, but the recent state and local solicitations tagged under it show little alignment with that narrow product scope. The two most recent opportunities — an Illinois Department of Public Health pharmaceutical warehouse piggyback contract and a Seminole County, Florida procurement for naloxone and drug deactivation systems — do not reference bekanamycin sulfate or products in its therapeutic class. Instead, the code appears to capture broader pharmaceutical inventory and emergency-response medication acquisitions by state health departments and county public-health authorities, though the specificity of the code name and the mismatch with actual sourced products suggest either miscoding in the state procurement systems or a data-import artifact. State and local issuers under this code include state departments of public health and county health authorities; recent activity does not support a pattern of repeat solicitation from a single buyer or jurisdiction.

The geographic spread reflects scattered activity across the South and Midwest, with documented recent opportunities in Illinois and Florida. The Illinois Department of Public Health awarded a $2,999,999.11 three-year piggyback pharmaceutical warehouse contract to Chartwell Rx LLC through the MMCAP Infuse consortium on August 28, 2026, under IFB 26482DPHPREPDB53392 for doxycycline hyclate and ciprofloxacin hydrochloride; that award closed before response deadline. Seminole County, Florida posted an IFB (60459723LAS) on June 30, 2026, with a July 26, 2023 response date (note date inconsistency in source), seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. Neither opportunity explicitly tagged set-asides or business-enterprise preferences. Given the mismatch between the code's nominal pharmaceutical scope and the actual work being sourced, and the absence of current open solicitations directly for bekanamycin sulfate or related products, this code shows minimal actionable recent activity for business development targeting.